Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas
NCT03784014Phase 3Completed
- Sponsor
- Inserm
- Start
- Oct 2019
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Antibody Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib, ceritinib, capmatinib, lapatinib, trametinib in soft tissue sarcoma (STS), sponsored by Inserm. Started Oct 2019; status: completed.
02
Drugs
nilotinibceritinibcapmatiniblapatinibtrametinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03784014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784014.